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Background The SYNTAX score (SXscore), an anatomical-based scoring tool reflecting the complexity of coronary anatomy, has
established itself as an important long-term prognostic factor in patients undergoing percutaneous coronary interven-
tion (PCI). The incorporation of clinical factors may further augment the utility of the SXscore to longer-term risk
stratify the individual patient for clinical outcomes.
Methods
and results
Patient-level merged data from .6000 patients in seven contemporary coronary stent trials was used to develop a
logistic regression model—the Logistic Clinical SXscore—to predict 1-year risk for all-cause death and major adverse
cardiac events (MACE). A core model (composed of the SXscore, age, creatinine clearance, and left ventricular ejec-
tion fraction) and an extended model [incorporating the core model and six additional (best performing) clinical vari-
ables] were developed and validated in a cross-validation procedure. The core model demonstrated a substantial
improvement in predictive ability for 1-year all-cause death compared with the SXscore in isolation [area under
the receiver operator curve (AUC): core model: 0.753, SXscore: 0.660]. A minor incremental benefit of the extended
model was shown (AUC: 0.791). Consequently the core model alone was retained in the final the Logistic Clinical
SXscore model. Validation plots confirmed the model predictions to be well calibrated. For 1-year MACE, the add-
ition of clinical variables did not improve the predictive ability of the SXscore, secondary to the SXscore being the
predominant determinant of all-cause revascularization.
Conclusion The Logistic Clinical SXscore substantially enhances the prediction of 1-year mortality after PCI compared with the
SXscore, and allows for an accurate personalized assessment of patient risk.
Introduction
The SYNTAX score1 – 4 (SXscore) has established itself as an im-
portant prognostic tool in risk stratifying patients in the Synergy
between Percutaneous Coronary Intervention with Taxus and
Cardiac Surgery (SYNTAX) pioneered Heart Team approach,
and has since been validated in patients undergoing percutaneous
coronary intervention (PCI) at a short and longer-term follow-
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up.5 –9 More recently the SXscore has been applied to contempor-
ary ‘All-Comers’ coronary stent trials, and has consistently been
shown to be an independent predictor of 1-year mortality and
major adverse cardiac events (MACE).10–12 In contrast, traditional
risk scores for patients undergoing PCI principally allow for the
estimation of procedural risk.13–18
The addition of clinical risk factors to the SXscore has been
shown to potentially further augment its utility to objectively
select the most appropriate revascularization strategy for patients
planning to undergo surgical or percutaneous revascularization.19–23
These approaches have involved the amalgamation of cardiac
surgery-based summary risk scores to the SXscore to form the
‘Global Risk’ (SXscore and additive EuroSCORE)23 and the ‘clinical
SXscore’ (SXscore and the modified ACEF score).19–22 As the in-
dividual clinical components of the cardiac surgery-based summary
risk scores were not incorporated into the development of the
combined risk models, and that these risk scores contained redun-
dant information not relevant to the prediction of mortality after
PCI—such as the chronic obstructive pulmonary disease and pul-
monary hypertension in the EuroSCORE—this may have limited
the predictive ability of the final risk models.23 Furthermore,
these approaches categorized patient risk without giving a more
personalized risk assessment—with the Clinical SXscore19– 22
being able to identify a high-risk population only, and the Global
Risk23 a lower-risk population.
The aims of the present study are to combine the individual
components of the Clinical SXscore—namely the continuous vari-
ables age, creatinine or creatinine clearance (CrCl), left ventricular
ejection fraction (LVEF), and the SXscore—to form the Logistic
Clinical SYNTAX score (Logistic Clinical SXscore). The underlying
hypothesis being that the addition of these ‘Core’ clinical variables
would provide the majority of the improvement to the 1-year pre-
dictive ability of the SXscore compared with the addition of further
clinical variables. The second aim of this study was to allow for a
more personalized approach to risk stratification, compared with
the categorical approaches of previous risk models.19– 23
Methods
Patients
Patient-level data from seven contemporary coronary stent trials3,24–29
incorporating 6508 patients with a calculated SXscore were pooled
for the present study and have previously been described.19 An add-
itional trial was excluded from the original database (n ¼ 187)30 due
to permission being unobtainable from the study sponsor, and a
further 12 patients excluded due to missing values for death, leading
to a total of 6309 patients in the present analysis. The endpoints
for the prognostic analyses were 1-year all-cause death and MACE
[a composite of all-cause death, myocardial infarction (MI) and all-
cause revascularization].
Predictors and model development
During the development phase, two risk models were defined: (i) a
core model that incorporated the SXscore and components of the
ACEF and modified ACEF scores31 (age, creatinine or CrCl and
LVEF); (ii) an extended model that included the core model and the
addition of best performing clinical variables that improved the
performance of the core model. The CrCl was defined by the Cock-
croft and Gault formula.32 The left ventricular ejection fraction was
defined as the percentage LVEF taken by transthoracic echocardiog-
raphy or left ventriculography taken at the time of the diagnostic cor-
onary angiogram.
As the Logistic Clinical SXscore was to be developed for predicting
future longer-term (1-year) clinical outcomes, relatively weaker predic-
tors (of borderline significance) were selected and retained in the
extended model only if there was an appropriate increase in AUC
when added to the core model in the multivariable logistic regression
model, in line with work described by Harrell and others.33,34
Within all the coronary stent trials predictor values generally were
.90% complete if the predictor was recorded. Multiple imputation of
missing values in the trials with predictors recorded was undertaken
using an advanced imputation strategy that takes the correlation
between all potential predictors into account [method of chained
equations (MICE algorithm in R software)].35– 37
Statistical analysis
Logistic regression analyses were performed to examine individual and
joint relations between the core model, other clinical characteristics
(extended model), and the binary outcome of 1-year all-cause death
and MACE. Interaction terms between predictors were examined
with likelihood ratio tests, but none was of sufficient relevance to
extend the models beyond the main effects for each predictor. All ana-
lyses were stratified by the coronary stent trial.
Determining how the variables should be modelled was a vital step
in identifying which variables were most strongly related to 1-year clin-
ical outcomes. For the continuous predictors, possible non-linearity
with clinical outcomes was assessed with restricted cubic spline func-
tions. These are flexible functions that can accommodate curves in the
form of the association to assess the assumption that patient charac-
teristics are linearly related to the log odds of the outcome
event.33,34 To allow for a direct comparison of the prognostic value
of predictors recorded in different units or scales, the odds ratios
(ORs) for continuous predictors were scaled to correspond to a
change from the 25th to 75th percentile of the predictor distribu-
tion.37 Pooled ORs were estimated over the imputed data set, and
repeated using only the complete data, which gave similar results (un-
published data). Statistical analyses were performed with R software37
and SPSS Version 17.0 (SPSS, Inc., Chicago IL, USA).
Validation
The predictive performance of the model was cross-validated by the
omission of each of the coronary stent trials in turn, with the model
fitted on the remaining pooled population, and the resulting fit
tested on the omitted trial.38–40 This methodology allowed for the es-
timation of the extent to which the predictive accuracy of the model
(based on the entire sample) was affected by any differences
between the seven coronary stent trials.3,24–29 This form of cross-
validation by trial was hence a stronger test of validity than if, for
example, the study population had been divided at random into a de-
velopment and validation cohort.34,41,42
The measure of predictive discrimination used to characterize the
model performance in the original and the validation samples, was
by the area under the receiver operating characteristic curve (AUC),
and is equal to the c-statistic (the ability to distinguish a patient with
and without a clinical outcome—and ranges from 0.50 (no better
than flipping a coin) to 1.0 (model is 100% correct). Calibration—
the agreement between observed and predicted risks—was assessed
with the Hosmer–Lemeshow test and validation plots.33,40
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Model presentation
The final model is presented in a score chart with the scores based on
the original logistic regression coefficients and can be used to obtain
approximate predictions for individual patients.34,40 Scores were
based on rounding of the regression coefficients. A constant was sub-
tracted or added to rescale the scores in positive integers. The sum
scores were related to the risks of 1-year mortality with logistic regres-
sion. The score chart can be used to obtain approximate predictions
for individual patients.
Results
Development of the model
Within the analysed data set 175 all-cause deaths (2.8%) and 797
MACE (15.8%) were observed. The univariate associations of the
SXscore and clinical variables to 1-year all-cause death and
MACE are shown in Table 1. Creatinine clearance was
demonstrated to be a stronger univariate predictor of 1-year all-
cause death compared with serum creatinine and was therefore
incorporated into the core model (CrCl, OR: 2.2; 95% CI: 1.8–
2.8; creatinine, OR: 1.4; 95% CI: 1.2–1.6). Linear relationships
were a good approximation for the SXscore, age, CrCl, and
LVEF with 1-year mortality, except that constant risk was
evident at higher values for the LVEF (≥50%) and CrCl
(≥90 mL/min) (Supplementary material online, Appendix). The
four factors (SXscore, age, CrCl, and LVEF) were entered into a
multivariable logistic regression model (Table 2) and confirmed
to be strong independent predictors of 1-year mortality, thus
forming the core model.
Similar analyses were repeated with the core model and the best
performing clinical variables (six clinical variables: presentation,
body mass index (BMI), peripheral vascular disease, diabetes, pre-
vious MI, smoking) for 1-year mortality to form the extended
model.
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Table 1 Univariate associations between predictors of 1-year death and 1-year major adverse cardiac events in the
pooled database of seven contemporary coronary stent trials
Characteristics Coding Death (n5 6309) MACE (n 5 5048)a
Number (%) Univariateb Number (%) Univariateb
Core model
SYNTAX scorec 23 vs. 8 — 1.7 (1.6–1.8) — 1.8 (1.7–1.8)
Age (years)c 72 vs. 56 — 2.9 (2.7–3.1) — 1.2 (1.2–1.2)
CrClc 67 vs. 109 — 2.2 (1.8–2.6) — 1.2 (1.1–1.3)
Ejection fractiond 40 vs. 50 — 2.2 (1.8–2.8) — 1.3 (1.1–1.5)
Extended model
Presentation (%)
Stable 72 (2.4) 1.0 386 (15.1) 1.0
UA 32 (2.5) 1.0 (0.7–1.6) 185 (15.2) 1.0 (0.8–1.2)
NSTEMI 25 (3.1) 1.8 (1.1–2.9) 102 (16.5) 1.1 (0.8–1.4)
STEMI 46 (3.6) 1.7 (1.1–2.9) 97 (14.9) 1.0 (0.8–1.3)
Female 58 (3.7) 1.5 (1.1–2.1) 215 (17.1) 1.2 (1.0–1.4)
BMIc 30 vs. 25 — 1.1 (1.0–1.1) — 1.0 (1.0–1.1)
PVD 20 (6.9) 2.5 (1.5–4.1) 49 (20.6) 1.3 (0.9–1.8)
Diabetes (%)
Non-insulin treated 32 (3.8) 1.8 (1.2–2.8) 146 (17.4) 1.3 (1.1–1.6)
Insulin treated 27 (6.8) 3.1 (2.0–4.8) 101 (25.4) 2.1 (1.6–2.6)
Hypertension (%) 134 (3.1) 1.5 (1.1–2.2) 579 (16.1) 1.2 (1.0–1.5)
Hyperlipidaemia (%) 95 (2.3) 0.6 (0.5–0.9) 523 (15.3) 1.0 (0.9–1.2)
Glycoprotein 2b3a use (%) 57 (3.3) 1.2 (0.8–1.9) 173 (16.3) 1.1 (0.9–1.4)
Previous smoking (%) 48 (2.3) 0.8 (0.6–1.2) 259 (13.9) 1.0 (0.8–1.2)
Current smoking (%) 37 (2.2) 0.8 (0.5–1.1) 178 (14.3) 0.9 (0.7–1.1)
Previous MI (%) 68 (3.9) 1.8 (1.3–2.4) 250 (16.8) 1.2 (1.0–1.4)
Previous PCI (%) 23 (1.9) 0.7 (0.4–1.1) 179 (16.9) 1.2 (0.9–1.4)
TIA or CVA (%) 10 (5.5) 1.5 (0.7–2.8) 33 (22.8) 1.4 (0.9–2.1)
Stent generation (%) Newer generation 58 (2.1) 0.9 (0.5–1.6) 382 (14.1) 0.8 (0.6–1.1)
CrCl, creatinine clearance; Yrs, years; UA, unstable angina; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; BMI, body mass index;
PVD, peripheral vascular disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack; CVA, cerebrovascular accident.
an ¼ 5048 without STRATEGY/MULTI-STRATEGY24,28 and SIRTAX26 trials secondary to all-cause revascularization not being recorded in the trials.
bOdds ratio (95% confidence interval).
cOdds ratios for continuous variables are given for the inter-quartile range.
dOdds ratio for a decrease in 10% for values below 50%.
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Model performances
1-Year all-cause death (death)
The core model (SXscore, age, CrCl, and LVEF) demonstrated a
significantly better predictive ability for 1-year all-cause death com-
pared with the SXscore in isolation (Table 3). Within the pooled
population (combining all trials), the AUC was substantially
higher for the core model compared with the SXscore in isolation
(core model: 0.753, SXscore 0.660). A minor incremental benefit
of the extended model (AUC: 0.791) compared with the core
model was evident. Consequently, the core model was retained
in the final Logistic Clinical SXscore, and the extended model
excluded. The Hosmer–Lemeshow test confirmed that there
was no evidence of poor calibration for the core model in
pooled analyses of the seven trials (P ¼ 0.55). Validation plots of
the core model indicated a good agreement between the observed
and predicted risks in the three largest coronary stent trials
(n . 1000) (Figure 1). Within the SYNTAX trial recalibration of
the validation plots was necessary to prevent generalized under-
estimation of predicted risk, and involved resetting the intercept
of the calibration slope to zero.
1-Year major adverse cardiac events
For the outcome of 1-year MACE, the core and extended models
added little incremental increase in predictive ability compared
with the SXscore in isolation (AUC core model: 0.609, AUC
extended model: 0.618, SXscore: 0.605) (Tables 2 and 3).
Further analyses indicated that all-cause revascularization least
benefited from the addition of clinical variables compared with
death or MI (Supplementary material online, Appendix). Since
the Logistic Clinical SXscore conferred no major additional
benefit to the SXscore in predicting MACE, further analyses for
this endpoint are not reported.
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Table 3 Performances of the Logistic Clinical SYNTAX score (core model) at cross-validation
Study Death MACE
SYNTAX score Core model SYNTAX score Core model
ARTS II25 0.69 0.75 0.69 0.70
LEADERS27 0.63 0.74 0.62 0.61
STRATEGY24/MULTI-STRATEGY28 0.62 0.84 — —
RESOLUTE29 0.57 0.77 0.63 0.63
SIRTAX26 0.64 0.71 — —
SYNTAX3 0.67 0.73 0.58 0.59
Overalla 0.660 0.753 0.605b 0.609b
The core model was developed by omitting each study in turn, with the model fitted on the remaining pooled population, and validated by testing the resulting fit on the omitted
trial.38– 40 Values shown are c-statistics for testing the resulting fit on the omitted trial (cross-validation).
LEADERS, biolimus-eluting stent with biodegradable polymer vs. sirolimus-eluting stent with durable polymer for coronary revascularization trial;27 MACE, major adverse cardiac
events; RESOLUTE, RESOLUTE all-comers trial;29 SIRTAX, the sirolimus-eluting vs. paclitaxel-eluting stents for coronary revascularization trial;26 SYNTAX, Synergy between PCI
with Taxus and cardiac surgery trial;3 ARTS II, the arterial revascularization therapies study part II trial;25 STRATEGY, the single high-dose bolus tirofiban and sirolimus-eluting
stent vs. abciximab and bare metal stent in myocardial infarction trial;24 MULTISTRATEGY, comparison of angioplasty with infusion of tirofiban or abciximab and with implantation
of sirolimus-eluting or uncoated stents for acute myocardial infarctiontrial.28
aPooled population (combining all trials).
bn ¼ 5048 without STRATEGY/MULTI-STRATEGY and SIRTAX secondary to all-cause revascularization not being recorded in the trial.
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Table 2 Multivariable associations [odds ratio (95% CI)], between the individual components of the core model, for
1-year death and 1-yearmajor adverse cardiac events in the pooled database of seven contemporary coronary stent trials
Characteristics Coding Death (n5 6309) MACE (n 5 5048)a
Core model
SYNTAX Scoreb 23 vs. 8 1.41 (1.15–1.73) 1.72 (1.54–1.91)
Age (years)b 72 vs. 56 2.06 (1.51–2.82) 1.06 (0.92–1.22)
CrCl (ml/min)b 67 vs. 109 1.53 (1.12–2.09) 1.11 (0.94–1.31)
LVEF (%)c 40 vs. 50 1.97 (1.61–2.41) 1.10 (0.93–1.30)
CrCl, creatinine clearance, LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events.
an ¼ 5048 without STRATEGY/MULTI-STRATEGY24,28 and SIRTAX26 trials secondary to all-cause revascularization not being recorded in the trials.
bOdds ratios for continuous variables are given for the inter-quartile range (indicated in coding column).
cOdds ratio for a decrease in 10% for values ,50%.
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Score charts for 1-year all-cause death
A simple score chart for the bedside application of the final Logistic
Clinical SXscore for predicting 1-year all-cause death after PCI is illu-
strated (Figure 2). An extra score is included for a ‘‘SYNTAX-like’’
patient, i.e. a patient presenting with left main disease (isolated or
associated with 1, 2, or 3-vessel disease) or 3-vessel disease, due
to the need to recalibrate risks to the SYNTAX trial patients as
described previously. One-year mortality can be accurately esti-
mated by the summation of scores. Similar charts for the extended
model are enclosed in the Supplementary material online, Appendix.
Discussion
The main findings from this study are that: (i) the Logistic Clinical
SXscore—consisting of four continuous variables (SXscore, age,
CrCl, LVEF)—substantially enhances the risk stratification of PCI
patients for the outcome of 1-year all-cause death compared
with the SXscore in isolation; (ii) the Logistic Clinical SXscore
was able to accurately distinguish patients with or without a clinical
outcome (discrimination) and could accurately predict individual
patient risk (calibration) without under or over-estimating risk;
(iii) the addition of further clinical variables to the four key predic-
tors of the Logistic Clinical SXscore (SXscore, age, CrCl, and
LVEF) did not substantially increase its predictive ability; (iv) an
individualized approach to the longer-term (1-year) risk stratifica-
tion of patients after PCI was achievable utilizing the SXscore and
(v) the SXscore in isolation was the predominant determinant of
1-year MACE with little additional predictive benefit of clinical
variables, predominantly secondary to the SXscore being the
main determinant of all-cause revascularization.
Figure 1 Validation plots at cross-validation for the three largest coronary stent trials (n. 1000). Plots are shown for the core model pre-
dicting 1-year all-cause death. The triangles indicate the observed frequencies by quintile of predicted probabilities with a 95% confidence inter-
val. Good agreement was evident between observed and predicted risks, indicating that the core model did not over or under-estimate 1-year
mortality (i.e. good calibration).
Figure 2 The Logistic Clinical SYNTAX score for the prediction of 1-year death. *SYNTAX-like patient defined as fulfilling the enrolment
criteria for the SYNTAX All-Comers trial, i.e. left main stem (isolated or associated with one-, two-, or three-vessel disease) or three-vessel
disease alone. CrCl, creatinine clearance, LV ejection fraction, left ventricular ejection fraction.
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The logistic clinical SYNTAX score:
predicting 1-year death
The findings of the Logistic Clinical SXscore, namely that a few
strongly predictive clinical variables leading to the accurate predic-
tion of 1-year all-cause death after PCI, are consistent with the
concepts of the ‘‘law of parsimony’’ or ‘‘Occam’s razor.’’ Age,
CrCl, and LVEF are objectively measured continuous clinical vari-
ables in line with the ACEF methodology, which has previously
been shown to match or even surpass the EuroSCORE (consisting
of 17 clinical variables) in predicting in-hospital mortality after
elective coronary artery bypass graft surgery.31,43,44 Explanations
for this comparability have included that the clinical variables of
the ACEF score were objectively defined and continuous.31
Notably the addition of a further six clinical variables to the Lo-
gistic Clinical SXscore to form the extended model lead to a minor
incremental increase in its predictive ability. This is likely related to
the inter correlation between the core model and the additional
clinical variables. Clear correlations were evident (Pearson correl-
ation coefficient 0.2 or greater, P, 0.001) for age and gender/
hypertension; CrCl and gender/BMI; LVEF and MI; SXscore and
prior PCI; BMI and diabetes mellitus. In addition the presence of
diabetes has historically been associated with adverse outcomes
after PCI.45,46 It is however likely that patients with more severe
diabetes were captured by the continuous variables in the Logistic
Clinical SXscore, in particular a reduced CrCl. Both a reduced
CrCl and proteinuria—a marker of diabetic nephropathy—have
previously been shown to be significant determinants of adverse
risk following PCI.47–49 Furthermore diabetics without evidence of
proteinuria have also previously been reported to have a similar
survival compared with non-diabetics.47
SYNTAX score
The SXscore calculation has previously been reported to have
moderate inter-observer variability when performed by interven-
tional cardiologists,4,50 which may be perceived as a limitation of
the Logistic Clinical SXscore. Appropriate training of SXscore
reporting has, however, been shown to substantially reduce in-
ter-observer variability.1,2,50 It has previously been suggested that
the SXscore is a reflection of the underlying co-morbidity of the
patient,23 for which the present study provides further supportive
evidence. This notion is also supported by the 10-year predicted
Framingham risk scores being recently shown to have a significant
and direct relationship with the prevalence and magnitude of
coronary artery calcium scores.51
Comparisons with the clinical SYNTAX
score
The Clinical SXscore, on which the Logistic Clinical SXscore is
based, multiplied a variant of the surgical-based ACEF (age, creatin-
ine, and ejection fraction) score (modified ACEF score) to the
SXscore. In doing so the Clinical SXscore was shown to over-
estimate predicted risks (i.e. relatively poor calibration) despite
modest increases in the discriminative ability of the Clinical
SXscore being obtained.20,23 The application of the Clinical
SXscore to the present study (full data not shown) showed that
it was able to identify a high-risk population only (mortality: 6.6%
of the study population), compared with the intermediate- and
low-risk groups (mortality: 2.3 and 1.1% of the study population,
respectively) consistent with the previously reported litera-
ture.19– 23 Comparatively the Logistic Clinical SXscore within the
present study was demonstrated to accurately predict risk across
all risk groups (i.e. well calibrated) and importantly was able to
provide an individualized risk assessment.
Comparisons with other risk models
The recently reported Functional SXscore (FSS)—a fractional flow
reserve (FFR)-guided SYNTAX scoring methodology—has been
shown to potentially improve the predictive accuracy of the
SXscore.52 Within this study, the more objective assessment of
coronary stenoses compared with visual assessment (to form the
FSS) lead to incremental increases in the predictive accuracies
for the outcomes of 1-year MACE (AUC: SXscore, 0.630; FSS,
0.677), 1-year death or MI (AUC: SXscore, 0.621; FSS, 0.676)
and 1-year all-cause revascularization (AUC: SXscore, 0.627; FSS,
0.657).52 Notably, improvements in the predictive accuracy for
1-year death were not reported with the FSS. Comparatively the
Logistic Clinical SXscore in the present study demonstrated a sub-
stantial increase in the prediction of 1-year death (AUC: SXscore,
0.660; core model, 0.753), and improvements in the prediction of
1-year death or MI (AUC: SXscore, 0.594; core model, 0.657,
extended model 0.666—Supplementary material online, Appen-
dix) without the need for invasive pressure-wire coronary
assessment.
The longer-term (1-year) mortality predictions provided by the
Logistic Clinical SXscore are the principle differences compared
with other reported risk scores, namely the National Cardio-
vascular Data Registry16 score, the Mayo Clinical Risk score,13,15
the EuroHeart PCI score,18 and the New York PCI risk score,14
in that they report in-hospital Death14,16,18 or in-hospital
MACE,50,51 or at the most 30-day mortality16 after PCI. Other
risk scores that longer-term risk stratify patients include the
New Risk Stratification score (NERS).53 As previously described
with the Clinical SXscore, NERS categorized patients into levels
of risk (high and low risk) without giving an individualized assess-
ment of patient risk, which was achievable with the Logistic Clinical
SXscore. Furthermore NERS is a more complicated score that
consists of 17 clinical variables, 33 anatomical factors, and 4
procedural details, and was developed for patients with left main
coronary artery disease undergoing PCI.53
Potential clinical application
Although the patient and clinician may wish to know the short-
term risk of procedural complications associated with PCI, a
longer-term perspective may also be beneficial. Not only would
this appropriately inform the patient, but may also prove to be
of benefit in determining whether surgical or percutaneous re-
vascularization would be more appropriate as part of the Heart
Team consensus. As recently reported, high co-morbidity patients
may confer prognostic and morbidity benefits from undergoing
surgical revascularization compared with PCI provided a certain
threshold of operative risk is not exceeded.23
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Limitations
Although the Logistic Clinical SXscore was derived from ‘All-
Comers’ types patients in contemporary stent trials, each trial
still retained certain inclusion and exclusion criteria.11 These cri-
teria were, however, minimal which should legitimize the applica-
tion of the Logistic Clinical SXscore to contemporary clinical
practice. The authors recognize that further external validation
of the Logistic Clinical SXscore in ‘real-world’ ‘unrestricted’ regis-
try populations is necessary when these registries reporting the
SXscore become available. This would further strengthen the
results of this study, although the present analyses were already
undertaken in a pooled analysis of seven different contemporary
stent trials and internally validated with a cross-validation proced-
ure. Comparisons of the Logistic Clinical SXscore with the Global
Risk23 were not possible since the EuroSCORE was not collected
in the seven contemporary stent trials.
Cardiogenic shock is a risk variable that has consistently been
shown to be a powerful predictor of in-hospital mortality.13–18
This important subset of patients, although not an exclusion
criteria in the ‘All-Comers’ trials, by practice lead to the under-
recruitment of these patient types predominantly due to the inabil-
ity to gain appropriate informed consent or refusal to participate.54
Consequently, the Logistic Clinical SXscore should at present not
be applied to these patients where other risk scores would be
better suited.13–18
Future directions
Potentially the integration of the Logistic Clinical SXscore into an
online algorithm with the currently available SXscore1 may serve
to simultaneously allow for risk stratification of patients based on
anatomical and clinical variables. In addition, the application of
the Logistic Clinical SXscore in place of the SXscore to aid in
determining the optimal revascularization modality in patients
with complex coronary disease is a potential future application.
The incorporation of the FSS as previously described,52 to
allow for a more objective assessment of the coronary
anatomy, may enhance the predictive accuracy of the Logistic
Clinical SXscore even further. Future direction with non-invasive
imaging and FFR calculation55—utilizing computational fluid dynam-
ics applied to coronary computed tomography angiography—may
be feasible. The expansion of other risk variables to the Logistic
Clinical SXscore such as the haemodynamic status as previously
discussed may expand the use of this risk score to other patient
types.
Conclusion
Compared with the SXscore in isolation, the Logistic Clinical
SXscore substantially enhances the risk stratification of PCI
patients for death at 1-year and allows for an accurate individua-
lized assessment of patient risk. The use of the Logistic Clinical
SXscore may also further aid in the Heart Team consensus in
determining the optimal revascularization modality.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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